The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2020 | Update on IMGN632: CD123 antibody-drug conjugate for R/R AML and BPDCN
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase I/II study (NCT03386513) of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Additionally, Dr Daver outlines the Phase Ib/II study of IMGN632 study (NCT04086264) as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
